Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 182 entries
Sorted by: Best Match Show Resources per page
Role of the Three-Phase Boundary of the Platinum-Support Interface in Catalysis: A Model Catalyst Kinetic Study.

ACS catalysis

Papaioannou EI, Bachmann C, Neumeier JJ, Frankel D, Over H, Janek J, Metcalfe IS.
PMID: 27668125
ACS Catal. 2016 Sep 02;6(9):5865-5872. doi: 10.1021/acscatal.6b00829. Epub 2016 Jul 22.

A series of microstructured, supported platinum (Pt) catalyst films (supported on single-crystal yttria-stabilized zirconia) and an appropriate Pt catalyst reference system (supported on single-crystal alumina) were fabricated using pulsed laser deposition and ion-beam etching. The thin films exhibit area-specific...

Cite
Papaioannou EI, Bachmann C, Neumeier JJ, et al. Role of the Three-Phase Boundary of the Platinum-Support Interface in Catalysis: A Model Catalyst Kinetic Study. ACS Catal. 2016;6(9):5865-5872doi: 10.1021/acscatal.6b00829.
Papaioannou, E. I., Bachmann, C., Neumeier, J. J., Frankel, D., Over, H., Janek, J., & Metcalfe, I. S. (2016). Role of the Three-Phase Boundary of the Platinum-Support Interface in Catalysis: A Model Catalyst Kinetic Study. ACS catalysis, 6(9), 5865-5872. https://doi.org/10.1021/acscatal.6b00829
Papaioannou, Evangelos I, et al. "Role of the Three-Phase Boundary of the Platinum-Support Interface in Catalysis: A Model Catalyst Kinetic Study." ACS catalysis vol. 6,9 (2016): 5865-5872. doi: https://doi.org/10.1021/acscatal.6b00829
Papaioannou EI, Bachmann C, Neumeier JJ, Frankel D, Over H, Janek J, Metcalfe IS. Role of the Three-Phase Boundary of the Platinum-Support Interface in Catalysis: A Model Catalyst Kinetic Study. ACS Catal. 2016 Sep 02;6(9):5865-5872. doi: 10.1021/acscatal.6b00829. Epub 2016 Jul 22. PMID: 27668125; PMCID: PMC5031120.
Copy Download .nbib Format: NLM
Computing excess functions of ionic solutions: the smaller-ion shell model versus the primitive model. 1. Activity coefficients.

Journal of chemical theory and computation

Fraenkel D.
PMID: 26574216
J Chem Theory Comput. 2015 Jan 13;11(1):178-92. doi: 10.1021/ct5006938.

The present study compares the Monte Carlo (MC) simulation of the primitive model (PM) ( Abbas, Z. et al. J. Phys. Chem. B 2009 , 113 , 5905 ), by which activity coefficients of many binary ionic solutions have...

Cite
Fraenkel D. Computing excess functions of ionic solutions: the smaller-ion shell model versus the primitive model. 1. Activity coefficients. J Chem Theory Comput. 2015;11(1):178-92doi: 10.1021/ct5006938.
Fraenkel, D. (2015). Computing excess functions of ionic solutions: the smaller-ion shell model versus the primitive model. 1. Activity coefficients. Journal of chemical theory and computation, 11(1), 178-92. https://doi.org/10.1021/ct5006938
Fraenkel, Dan. "Computing excess functions of ionic solutions: the smaller-ion shell model versus the primitive model. 1. Activity coefficients." Journal of chemical theory and computation vol. 11,1 (2015): 178-92. doi: https://doi.org/10.1021/ct5006938
Fraenkel D. Computing excess functions of ionic solutions: the smaller-ion shell model versus the primitive model. 1. Activity coefficients. J Chem Theory Comput. 2015 Jan 13;11(1):178-92. doi: 10.1021/ct5006938. PMID: 26574216.
Copy Download .nbib Format: NLM
Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity.

Clinical pharmacology : advances and applications

Frankel AE.
PMID: 24353448
Clin Pharmacol. 2013 Nov 26;5:1-3. doi: 10.2147/CPAA.S55613. eCollection 2013.

No abstract available.

Cite
Frankel AE. Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity. Clin Pharmacol. 2013;5:1-3doi: 10.2147/CPAA.S55613.
Frankel, A. E. (2013). Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity. Clinical pharmacology : advances and applications, 51-3. https://doi.org/10.2147/CPAA.S55613
Frankel, Arthur E. "Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity." Clinical pharmacology : advances and applications vol. 5 (2013): 1-3. doi: https://doi.org/10.2147/CPAA.S55613
Frankel AE. Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity. Clin Pharmacol. 2013 Nov 26;5:1-3. doi: 10.2147/CPAA.S55613. eCollection 2013. PMID: 24353448; PMCID: PMC3860356.
Copy Download .nbib Format: NLM
Feasibility of Transseptal Access in Patients With Previously Scarred or Repaired Interatrial Septum.

Journal of cardiovascular electrophysiology

Arkles J, Zado E, Supple G, Frankel DS, Callans D, Marchlinski F, Dixit S.
PMID: 26075504
J Cardiovasc Electrophysiol. 2015 Sep;26(9):963-968. doi: 10.1111/jce.12730. Epub 2015 Aug 17.

BACKGROUND: Many patients (pts) with interatrial septal repair (ASR) and/or multiple prior transseptal puncture (MTSP) are being referred for atrial fibrillation (AF) ablation. We examine the feasibility of repeat TSP in these settings.METHODS: Records were reviewed from a single...

Cite
Arkles J, Zado E, Supple G, et al. Feasibility of Transseptal Access in Patients With Previously Scarred or Repaired Interatrial Septum. J Cardiovasc Electrophysiol. 2015;26(9):963-968doi: 10.1111/jce.12730.
Arkles, J., Zado, E., Supple, G., Frankel, D. S., Callans, D., Marchlinski, F., & Dixit, S. (2015). Feasibility of Transseptal Access in Patients With Previously Scarred or Repaired Interatrial Septum. Journal of cardiovascular electrophysiology, 26(9), 963-968. https://doi.org/10.1111/jce.12730
Arkles, Jeffrey, et al. "Feasibility of Transseptal Access in Patients With Previously Scarred or Repaired Interatrial Septum." Journal of cardiovascular electrophysiology vol. 26,9 (2015): 963-968. doi: https://doi.org/10.1111/jce.12730
Arkles J, Zado E, Supple G, Frankel DS, Callans D, Marchlinski F, Dixit S. Feasibility of Transseptal Access in Patients With Previously Scarred or Repaired Interatrial Septum. J Cardiovasc Electrophysiol. 2015 Sep;26(9):963-968. doi: 10.1111/jce.12730. Epub 2015 Aug 17. PMID: 26075504.
Copy Download .nbib Format: NLM
Management of the Asymptomatic Patient After Catheter Ablation of Atrial Fibrillation.

Journal of atrial fibrillation

Frankel DS, Gerstenfeld EP.
PMID: 28496644
J Atr Fibrillation. 2010 Jan 01;2(4):219. doi: 10.4022/jafib.219. eCollection 2010.

Ablative therapy for atrial fibrillation is becoming more commonplace, and some minimally symptomatic or asymptomatic patients will be referred for ablative therapy. Reasons to ablate asymptomatic patients include young age and/or the presence of a tachycardia induced cardiomyopathy; in...

Cite
Frankel DS, Gerstenfeld EP. Management of the Asymptomatic Patient After Catheter Ablation of Atrial Fibrillation. J Atr Fibrillation. 2010;2(4):219doi: 10.4022/jafib.219.
Frankel, D. S., & Gerstenfeld, E. P. (2010). Management of the Asymptomatic Patient After Catheter Ablation of Atrial Fibrillation. Journal of atrial fibrillation, 2(4), 219. https://doi.org/10.4022/jafib.219
Frankel, David S, and Gerstenfeld, Edward P. "Management of the Asymptomatic Patient After Catheter Ablation of Atrial Fibrillation." Journal of atrial fibrillation vol. 2,4 (2010): 219. doi: https://doi.org/10.4022/jafib.219
Frankel DS, Gerstenfeld EP. Management of the Asymptomatic Patient After Catheter Ablation of Atrial Fibrillation. J Atr Fibrillation. 2010 Jan 01;2(4):219. doi: 10.4022/jafib.219. eCollection 2010. PMID: 28496644; PMCID: PMC4956201.
Copy Download .nbib Format: NLM
Doctors and the law.

Clinical medicine (Northfield, Ill.)

FRANKEL CJ.
PMID: 13701403
Clin Med (Northfield). 1961 Aug;8:1571-8.

No abstract available.

Cite
FRANKEL CJ. Doctors and the law. Clin Med (Northfield). 1961;8:1571-8
FRANKEL, C. J. (1961). Doctors and the law. Clinical medicine (Northfield, Ill.), 81571-8.
FRANKEL, C J. "Doctors and the law." Clinical medicine (Northfield, Ill.) vol. 8 (1961): 1571-8.
FRANKEL CJ. Doctors and the law. Clin Med (Northfield). 1961 Aug;8:1571-8. PMID: 13701403.
Copy Download .nbib Format: NLM
Food dye use in enteral feedings: a review and a call for a moratorium.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

Maloney JP, Ryan TA, Brasel KJ, Binion DG, Johnson DR, Halbower AC, Frankel EH, Nyffeler M, Moss M.
PMID: 16214982
Nutr Clin Pract. 2002 Jun;17(3):169-81. doi: 10.1177/0115426502017003169.

Pulmonary aspiration of gastric contents is common in enterally fed patients. Tinting enteral feedings with blue dye is thought to aid the early detection of aspiration in hospitalized patients. The blue-dye method is popular despite evidence that it is...

Cite
Maloney JP, Ryan TA, Brasel KJ, et al. Food dye use in enteral feedings: a review and a call for a moratorium. Nutr Clin Pract. 2002;17(3):169-81doi: 10.1177/0115426502017003169.
Maloney, J. P., Ryan, T. A., Brasel, K. J., Binion, D. G., Johnson, D. R., Halbower, A. C., Frankel, E. H., Nyffeler, M., & Moss, M. (2002). Food dye use in enteral feedings: a review and a call for a moratorium. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 17(3), 169-81. https://doi.org/10.1177/0115426502017003169
Maloney, James P, et al. "Food dye use in enteral feedings: a review and a call for a moratorium." Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition vol. 17,3 (2002): 169-81. doi: https://doi.org/10.1177/0115426502017003169
Maloney JP, Ryan TA, Brasel KJ, Binion DG, Johnson DR, Halbower AC, Frankel EH, Nyffeler M, Moss M. Food dye use in enteral feedings: a review and a call for a moratorium. Nutr Clin Pract. 2002 Jun;17(3):169-81. doi: 10.1177/0115426502017003169. PMID: 16214982.
Copy Download .nbib Format: NLM
Classification of adverse events occurring in a surgical intensive care unit.

American journal of surgery

Frankel H, Sperry J, Kaplan L, Foley A, Rabinovici R.
PMID: 17693277
Am J Surg. 2007 Sep;194(3):328-32. doi: 10.1016/j.amjsurg.2007.02.009.

INTRODUCTION: We aimed to describe the preventability and provider specificity of surgical intensive care unit (SICU) deaths and complications compared with those in a cohort of trauma patients.METHODS: Data were collected on all trauma and SICU admissions from July...

Cite
Frankel H, Sperry J, Kaplan L, et al. Classification of adverse events occurring in a surgical intensive care unit. Am J Surg. 2007;194(3):328-32doi: 10.1016/j.amjsurg.2007.02.009.
Frankel, H., Sperry, J., Kaplan, L., Foley, A., & Rabinovici, R. (2007). Classification of adverse events occurring in a surgical intensive care unit. American journal of surgery, 194(3), 328-32. https://doi.org/10.1016/j.amjsurg.2007.02.009
Frankel, Heidi, et al. "Classification of adverse events occurring in a surgical intensive care unit." American journal of surgery vol. 194,3 (2007): 328-32. doi: https://doi.org/10.1016/j.amjsurg.2007.02.009
Frankel H, Sperry J, Kaplan L, Foley A, Rabinovici R. Classification of adverse events occurring in a surgical intensive care unit. Am J Surg. 2007 Sep;194(3):328-32. doi: 10.1016/j.amjsurg.2007.02.009. PMID: 17693277.
Copy Download .nbib Format: NLM
Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications.

The Journal of clinical and aesthetic dermatology

Frankel AJ, Zeichner JA, Del Rosso JQ.
PMID: 20967195
J Clin Aesthet Dermatol. 2010 Oct;3(10):42-5.

Psoriasis is a chronic, inflammatory, immune-mediated, multi-system disease that is treated with a variety of medicines, including topical corticosteroids and, historically, coal tar. In this case, the authors evaluated whether combination therapy with coal tar foam 2% and a...

Cite
Frankel AJ, Zeichner JA, Del Rosso JQ. Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications. J Clin Aesthet Dermatol. 2010;3(10):42-5
Frankel, A. J., Zeichner, J. A., & Del Rosso, J. Q. (2010). Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications. The Journal of clinical and aesthetic dermatology, 3(10), 42-5.
Frankel, Amylynne J, et al. "Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications." The Journal of clinical and aesthetic dermatology vol. 3,10 (2010): 42-5.
Frankel AJ, Zeichner JA, Del Rosso JQ. Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications. J Clin Aesthet Dermatol. 2010 Oct;3(10):42-5. PMID: 20967195; PMCID: PMC2958196.
Copy Download .nbib Format: NLM
Poliomyelitis; results of treatment.

Virginia medical monthly

FRANKEL CJ, CRALLE RL.
PMID: 21019754
Va Med Mon (1918). 1946 Apr;73:179.

No abstract available.

Cite
FRANKEL CJ, CRALLE RL. Poliomyelitis; results of treatment. Va Med Mon (1918). 1946;73:179
FRANKEL, C. J., & CRALLE, R. L. (1946). Poliomyelitis; results of treatment. Virginia medical monthly, 73179.
FRANKEL, C J, and CRALLE, R L. "Poliomyelitis; results of treatment." Virginia medical monthly vol. 73 (1946): 179.
FRANKEL CJ, CRALLE RL. Poliomyelitis; results of treatment. Va Med Mon (1918). 1946 Apr;73:179. PMID: 21019754.
Copy Download .nbib Format: NLM
HIV-1 Tat: Its Dependence on Host Factors is Crystal Clear.

Viruses

D'Orso I, Frankel AD.
PMID: 21709748
Viruses. 2010 Oct 01;2(10):2226-2234. doi: 10.3390/v2102226.

HIV-1 transcription is regulated at the level of elongation by the viral Tat protein together with the cellular elongation factor P-TEFb, which is composed of cyclin T1 and Cdk9 subunits. The crystal structure of a Tat:P-TEFb complex (Tahirov, T.H.;...

Cite
D'Orso I, Frankel AD. HIV-1 Tat: Its Dependence on Host Factors is Crystal Clear. Viruses. 2010;2(10):2226-2234doi: 10.3390/v2102226.
D'Orso, I., & Frankel, A. D. (2010). HIV-1 Tat: Its Dependence on Host Factors is Crystal Clear. Viruses, 2(10), 2226-2234. https://doi.org/10.3390/v2102226
D'Orso, Iván, and Frankel, Alan D. "HIV-1 Tat: Its Dependence on Host Factors is Crystal Clear." Viruses vol. 2,10 (2010): 2226-2234. doi: https://doi.org/10.3390/v2102226
D'Orso I, Frankel AD. HIV-1 Tat: Its Dependence on Host Factors is Crystal Clear. Viruses. 2010 Oct 01;2(10):2226-2234. doi: 10.3390/v2102226. PMID: 21709748; PMCID: PMC3120229.
Copy Download .nbib Format: NLM
Large Eddy Simulation of FDA's Idealized Medical Device.

Cardiovascular engineering and technology

Delorme YT, Anupindi K, Frankel SH.
PMID: 24187599
Cardiovasc Eng Technol. 2013 Dec 01;4(4). doi: 10.1007/s13239-013-0161-7.

A hybrid large eddy simulation (LES) and immersed boundary method (IBM) computational approach is used to make quantitative predictions of flow field statistics within the Food and Drug Administration's (FDA) idealized medical device. An in-house code is used, hereafter...

Cite
Delorme YT, Anupindi K, Frankel SH. Large Eddy Simulation of FDA's Idealized Medical Device. Cardiovasc Eng Technol. 2013;4(4)doi: 10.1007/s13239-013-0161-7.
Delorme, Y. T., Anupindi, K., & Frankel, S. H. (2013). Large Eddy Simulation of FDA's Idealized Medical Device. Cardiovascular engineering and technology, 4(4), . https://doi.org/10.1007/s13239-013-0161-7
Delorme, Yann T, et al. "Large Eddy Simulation of FDA's Idealized Medical Device." Cardiovascular engineering and technology vol. 4,4 (2013). doi: https://doi.org/10.1007/s13239-013-0161-7
Delorme YT, Anupindi K, Frankel SH. Large Eddy Simulation of FDA's Idealized Medical Device. Cardiovasc Eng Technol. 2013 Dec 01;4(4). doi: 10.1007/s13239-013-0161-7. PMID: 24187599; PMCID: PMC3810982.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 182 entries